Ignite Creation Date:
2024-05-05 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00105547
Status:
COMPLETED
Last Update Posted:
2009-05-05
First Post:
2005-03-15
Brief Title:
Efficacy Study of MPC-7869 to Treat Patients With Alzheimers
Sponsor:
Myrexis Inc
Organization:
Myrexis Inc
Study Overview
Official Title:
Phase 3 Multicenter Randomized Double Blind Placebo Controlled Study of the Effect of Daily Treatment With MPC-7869 on Measures of Cognition Activities of Daily Living and Global Function in Subjects With Mild Dementia of the Alzheimers Type
Status:
COMPLETED
Status Verified Date:
2009-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to evaluate the change in cognitive ability and activities of daily living in patients with Alzheimers disease AD as measured by specific evaluations during 18 months of dosing
Detailed Description:
This trial is a phase 3 multicenter randomized double-blind placebo controlled parallel group study comparing the safety and efficacy of daily dosing of MPC-7869 to placebo The study subjects will have the diagnosis of mild dementia of the Alzheimers type Subjects may be taking approved medication for Alzheimers disease provided the dose has been stable for at least 6 months
The primary objective of the study is to evaluate the change in cognition and activities of daily living
The primary objective of the study is to evaluate the change in cognition and activities of daily living
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None